+353-1-416-8900REST OF WORLD
1-800-526-8630U.S. (TOLL FREE)

Drug Self-Administration to 2022

  • ID: 3064212
  • Report
  • January 2015
  • Region: Global
  • Greystone Associates
1 of 4
Indications, Markets, Players, Strategies and Forecasts
While alternative methods for delivering therapeutics to patients have had some notable successes, most drugs continue to be delivered orally. Because they cannot tolerate the first-pass metabolism of the digestive tract, the recent escalation in new biological drugs, including antibodies and recombinant proteins, is placing renewed emphasis on alternate delivery technologies. Now a number of factors are converging to create both risk and opportunity for drug makers and their delivery device partners. These include new classes of drugs for previously refractory conditions, the growing trend toward self-administration for chronic diseases, shifting patient demographics in industrial countries, caregiver safety legislation, and continued pressure to control healthcare costs. These factors are giving rise to a new generation of sophisticated, application-specific injection, inhalation and transdermal drug products designed to satisfy caregiver and patient preferences while addressing managed care initiatives and the formulation limitations of new classes of therapeutic drugs. Because of their ability to safely and reliably satisfy treatment protocols and compliance goals, non-oral drug delivery products will have a significant impact on the future of drug self-administration.


- Provides detailed analysis of drug self-administration market segments, market dynamics and market demographics

- Analyzes therapeutic demand drivers and evaluates commercial drug products in more than two dozen major self-administration therapeutic segments

- Analyzes design factors, material selection issues, technologies and market development issues for injection devices, inhalation devices and transdermal drug products designed for self-administration

- Charts product data, market share, and forecasts to 2022

- Profiles self-administration drug product and device participants, their product development activities, business strategies, and corporate alliances and affiliations
Note: Product cover images may vary from those shown
2 of 4


3 of 4
1. Executive Summary

2. Drug Market Dynamics
- Evolving Drug Development and Market Factors
- Managed Care and Prescribing Trends
- Drug Self-Administration Demand Factors
- Shifting Patient Demographics
- Chronic Disease and Self-administration
- Biological Drugs Proliferating
- Delivery Device Technology & Evolving

3. Injectable Drug Self-Administration
- Market Sector Dynamics
- Prefilled Syringes (PFS)
- Glass PFS
- Plastic PFS
- Autoinjectors
- Pen Injectors
- Reusable Pens
- Disposable Pens
- Needle-free Injectors (NFI)
- Competitive NFI Therapeutic Segments
- Needle-free Company Profiles

4. Inhaled Drug Self-Administration Products
- Market Sector Dynamics
- The Upper Respiratory Market
- The Systemic/Deep Lung Market
- Inhaler Technology and Market Prospects
- Inhaler Product Segments
- Dry Powder Inhalers
- Metered Dose Inhalers
- Nebulizers
- Performance Factors
- Bioavailability
- Dose Reproducibility
- Active Compound Stability

5. Transdermal Drug Products
- Market Sector Dynamics
- Prescription Patch Design & Technology
- Active Transport Patch Technologies
- Prescription Patch Development Factors
- Key Transdermal Therapeutic Markets
- Transdermal Product Company Profiles

6. Drug Self-Administration: Therapeutic Sector Analysis & Forecasts
- Anticoagulants
- Arthritis
- Asthma/COPD
- Cardiovascular
- Contraception
- Cystic Fibrosis
- Diabetes
- Hematopoietics
- Hepatitis
- Hormone Therapy/Replacement
- Multiple Sclerosis
- Neurology
- Osteoporosis
- Pain Management
- Psoriasis
- Sexual Health
Note: Product cover images may vary from those shown
4 of 4
Note: Product cover images may vary from those shown